Veno Occlusive Disease News and Research

RSS
Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

CNDA approves KEYTRUDA for treatment of advanced melanoma

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

FDA approves drug to treat patients with newly diagnosed CD33-positive AML

FDA approves drug to treat patients with newly diagnosed CD33-positive AML

Pfizer receives FDA approval for new therapy to treat adults and children with AML

Pfizer receives FDA approval for new therapy to treat adults and children with AML

Researchers develop quick and easy-to-use test for detecting rare immunodeficiency

Researchers develop quick and easy-to-use test for detecting rare immunodeficiency

FDA approval provides new, targeted treatment option for adults with relapsed or refractory B-cell ALL

FDA approval provides new, targeted treatment option for adults with relapsed or refractory B-cell ALL

Experts develop new genomic testing method for pulmonary hypertension caused by genetic mutation

Experts develop new genomic testing method for pulmonary hypertension caused by genetic mutation

Salvage inotuzumab ozogamicin improves ALL outcomes

Salvage inotuzumab ozogamicin improves ALL outcomes

FDA approves Defitelio to treat hepatic veno-occlusive disease in adults, children

FDA approves Defitelio to treat hepatic veno-occlusive disease in adults, children

HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

Jazz Pharmaceuticals to present defibrotide results for hepatic VOD at BMT Tandem meetings

Jazz Pharmaceuticals to present defibrotide results for hepatic VOD at BMT Tandem meetings

Bayer HealthCare receives FDA approval for Adempas tablets

Bayer HealthCare receives FDA approval for Adempas tablets

Tacrolimus plus sirolimus not better than standard regimen in preventing GVHD

Tacrolimus plus sirolimus not better than standard regimen in preventing GVHD

University of Kentucky to host Makenna Foundation Symposium on Pediatric Pulmonary Disease

University of Kentucky to host Makenna Foundation Symposium on Pediatric Pulmonary Disease

New research on diagnosis and treatment of leukemia to be presented at 53rd ASH meeting

New research on diagnosis and treatment of leukemia to be presented at 53rd ASH meeting

FDA approves change to prescribing information for Gilead Sciences' Letairis

FDA approves change to prescribing information for Gilead Sciences' Letairis